Outlier in a BE study [Outliers]

posted by Helmut Homepage – Vienna, Austria, 2014-01-16 15:54 (3354 d 06:55 ago) – Posting: # 12181
Views: 8,803

Hi Kumar,

❝ FDA does not encourage redosing to handle outliers subjects incase of non-replicate design study…


❝ … wherein you may carry out redosing incase of replicate design.

I don’t think so – at least in a fully replicated design (see this post). In a partial replicate – if the “outlier” occurred after T – I would not perform a re-dosing study without contacting FDA OGD’s review stuff beforehand.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
 Admin contact
22,550 posts in 4,724 threads, 1,606 registered users;
17 visitors (0 registered, 17 guests [including 8 identified bots]).
Forum time: 22:49 CET (Europe/Vienna)

That which is static and repetitive is boring.
That which is dynamic and random is confusing.
In between lies art.    John Locke

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz